Molecular Partners AG (XSWX:MOLN) Accounts Receivable : CHF3.18 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Molecular Partners AG Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Molecular Partners AG's accounts receivables for the quarter that ended in Mar. 2024 was CHF3.18 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Molecular Partners AG's Days Sales Outstanding for the quarter that ended in Mar. 2024 was 105.95.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Molecular Partners AG's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was CHF4.85.

Molecular Partners AG Accounts Receivable Historical Data

The historical data trend for Molecular Partners AG's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Partners AG Accounts Receivable Chart

Molecular Partners AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Receivable

Get a 7-Day Free Trial

0.02

0.16

23.71

0.52

0.30

Molecular Partners AG Quarterly Data
	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Receivable	Get a 7-Day Free Trial															1.74	1.51	1.79	0.30	3.18

Molecular Partners AG Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Molecular Partners AG Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Molecular Partners AG's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	3.179	/	2.738	*	91
=	105.95

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Molecular Partners AG's accounts receivable are only considered to be worth 75% of book value:

Molecular Partners AG's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(174.133	+	0.75 * 3.179	+	0.5 * 0	-	17.06
-	0	-	0)	/	32.8689
=	4.85

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Molecular Partners AG Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Molecular Partners AG's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Molecular Partners AG (XSWX:MOLN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (XSWX:MOLN) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

MOLN:USA MLLCF:USA MOLNz:UK 6ML0:Germany

Address

Wagistrasse 14, Schlieren, Zurich, CHE, 8952

Website

https://www.molecularpartners.com

Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.